Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Cabozantinib improves PFS in metastatic renal cell carcinoma

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.10.16
Views: 1429

Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA

Dr Choueiri speaks with ecancertv at ESMO 2016 to discuss results from two trials for novel therapies against metastatic renal cell carcinoma (mRCC).

First, he discusses the comparative trial CABOSUN, investigating cabozantinib versus sunitinib, and then a phase 1b dose escalation of checkpoint inhibitor therapy in combination with axitinib.

Considering the results of these trials, Dr Choueiri describes his hopes for the future of mRCC care.

Video of the press conference in which the CABOSUN results were presented is available here, and details are available in the news coverage here.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation